Allison brings immunotherapy expertise to MD Anderson – Opportunity to combine immune therapies with targeted cancer drugs attracts scientist to MD Anderson. “It’s a chance to move to a place where things are really happening.” “The main reason for coming to MD Anderson is the opportunity offered by a clinical community that’s open to using immunological approaches to treat cancer combined with other therapies,” Allison said. “We plan to build a large platform where basic scientists interested in mouse models of cancer work side-by-side with physician-scientists who treat patients to analyze tissues from those patients and truly understand the mechanisms involved,” Allison said. “We can accelerate the transition of new combinations of drugs into the clinic beyond phase I clinical trials and broaden our focus beyond melanoma and prostate cancer to other types of cancer. “We all know that no single drug will cure cancer. I think this is where we’ll start getting cures, or at least long-term survival of patients. There’s lots of enthusiasm for this approach at MD Anderson and I’m really excited about it,” he said. Allison will play an instrumental role in MD Anderson’s recently announced Moon Shots Program to dramatically accelerate the pace of converting scientific discoveries into clinical advances that reduce cancer deaths. He is a member of the National Academy of Sciences and the Institute of Medicine, as well as a fellow of the American Academy of Microbiology and the American Association for the Advancement of Science. He …

From Twitter:

#Maryland #drugtreatment advocates protest millions of dollars in cuts to state #rehab programs. http://t.co/VMHbHo5Z #mdpolitics – by IlanaKowarski (Ilana Kowarski)